FDA-approved Heart & blood

Echinocandins

Echinocandins is a lipopeptide antifungals. It is filed in this library under heart & blood, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.

Regulatory status

Echinocandins has an FDA-approved product on the U.S. market, marketed as Caspofungin Acetate under application ANDA207092.

The current label is held by Sagent Pharmaceuticals.

From the FDA label

What Echinocandins is approved to treat

aspofungin acetate for injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. Treatment of esophageal candidiasis. Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies.Quoted from the FDA-approved prescribing information

The evidence

What has actually been published

2 sources on Echinocandins published between 2002 and 2007, each resolved to its journal of record. Titles are listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on heart & blood

Not sure what applies to you?

A 60-second questionnaire, reviewed by a U.S.-licensed physician.

Find my protocol

Educational reference only. This page explains what has been published about Echinocandins. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides